FDA — authorised 25 May 2004
- Application: NDA021361
- Marketing authorisation holder: SALIX PHARMS
- Local brand name: XIFAXAN
- Indication: TABLET — ORAL
- Status: approved
FDA authorised Rifaximin (drug) on 25 May 2004
Yes. FDA authorised it on 25 May 2004; FDA authorised it on 24 March 2010.
SALIX PHARMS holds the US marketing authorisation.